Chimeric Therapeutics Limited Stock Net Income
| CHMMF Stock | 0 0.00 0.00% |
Fundamental analysis of Chimeric Therapeutics allows traders to better anticipate movements in Chimeric Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Chimeric |
Chimeric Therapeutics Limited Company Net Income Analysis
Chimeric Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Chimeric Therapeutics Net Income | (15.9 M) |
Most of Chimeric Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chimeric Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Chimeric Therapeutics Limited reported net income of (15.9 Million). This is much lower than that of the sector and significantly lower than that of the Net Income industry. The net income for all United States stocks is notably higher than that of the company.
Chimeric Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chimeric Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Chimeric Therapeutics could also be used in its relative valuation, which is a method of valuing Chimeric Therapeutics by comparing valuation metrics of similar companies.Chimeric Therapeutics is currently under evaluation in net income category among its peers.
Chimeric Fundamentals
| Return On Equity | -0.63 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (5.57) % | |||
| Current Valuation | 56.81 K | |||
| Shares Outstanding | 437.09 M | |||
| Shares Owned By Insiders | 47.75 % | |||
| Price To Book | 1.49 X | |||
| Price To Sales | 10.02 X | |||
| Revenue | 2.62 M | |||
| Gross Profit | 2.62 M | |||
| EBITDA | (14.14 M) | |||
| Net Income | (15.9 M) | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (13.15 M) | |||
| Market Capitalization | 26.23 M | |||
| Total Asset | 34.88 M | |||
| Net Asset | 34.88 M |
About Chimeric Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chimeric Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chimeric Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chimeric Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Chimeric Pink Sheet
Chimeric Therapeutics financial ratios help investors to determine whether Chimeric Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Chimeric with respect to the benefits of owning Chimeric Therapeutics security.